GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » EV-to-FCF

Gyre Therapeutics (Gyre Therapeutics) EV-to-FCF : (As of May. 15, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Gyre Therapeutics's Enterprise Value is $1,309.0 Mil. Gyre Therapeutics does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Gyre Therapeutics's EV-to-FCF at this moment.

The historical rank and industry rank for Gyre Therapeutics's EV-to-FCF or its related term are showing as below:

GYRE' s EV-to-FCF Range Over the Past 10 Years
Min: 43.55   Med: 66.72   Max: 401.15
Current: 75.64

During the past 3 years, the highest EV-to-FCF of Gyre Therapeutics was 401.15. The lowest was 43.55. And the median was 66.72.

GYRE's EV-to-FCF is ranked worse than
84.62% of 390 companies
in the Biotechnology industry
Industry Median: 6.305 vs GYRE: 75.64

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), Gyre Therapeutics's stock price is $15.77. Gyre Therapeutics does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Gyre Therapeutics's PE Ratio at this moment.

Gyre Therapeutics EV-to-FCF Historical Data

The historical data trend for Gyre Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics EV-to-FCF Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EV-to-FCF
- - 113.51

Gyre Therapeutics Semi-Annual Data
Dec21 Dec22 Dec23
EV-to-FCF - - 113.51

Competitive Comparison of Gyre Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Gyre Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's EV-to-FCF falls into.


Gyre Therapeutics EV-to-FCF Calculation

Gyre Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1309.023/
=

Gyre Therapeutics  (NAS:GYRE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Gyre Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=15.77/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Gyre Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » EV-to-FCF
Comparable Companies
Traded in Other Exchanges
L9S:Germany
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Website
https://www.gyretx.com
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023